7月30日，百特国际盘中大幅上涨17.69%，报28.845美元/股，成交额1.1亿美元。
消息面上，公司于盘前发布第二季度财报，业绩全面超出市场预期。数据显示，百特国际Q2调整后每股收益为0.56美元，大幅超越市场一致预期的0.37美元，超出幅度逾50%；营收29.6亿美元，高于分析师预期的28亿美元，同比增长5.3%。与此同时，公司将全年调整后每股收益指引从此前的1.85至2.05美元上调至1.95至2.15美元，高于FactSet一致预期的1.92美元，进一步提振市场信心。
值得关注的是，财报发布前已有多家投行集中上调百特目标价，其中Stifel将目标价从19美元上调至24美元，Evercore ISI上调至24美元，高盛上调至21美元，反映机构对公司经营改善趋势的认可。百特国际是全球领先的医疗保健产品提供商，产品涵盖无菌静脉溶液、输液系统、肠外营养疗法、吸入麻醉剂及手术止血剂等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.